The Claim
East Asian individuals taking rosuvastatin exhibit a significantly higher incidence of liver enzyme elevation compared to other ethnic groups, and 73.7% of these affected East Asian patients carry the ABCG2 rs2231142 variant, indicating a population-specific pharmacogenomic association.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
East Asian people taking rosuvastatin are more likely to show elevated liver enzymes than people from other ethnic groups, and 73.7% of those with elevated enzymes carry a specific genetic variant called ABCG2 rs2231142.
See the scientific wording
East Asian individuals taking rosuvastatin have a significantly higher incidence of liver enzyme elevation compared to other ethnic groups, with 73.7% of affected East Asian patients carrying the ABCG2 rs2231142 variant, suggesting population-specific pharmacogenomic risk.
A genetic change in the liver reduces the ability of liver cells to push rosuvastatin out into bile, so the drug builds up inside the cells. This buildup damages the energy-producing parts of the cells, causing them to leak enzymes into the blood.
What the research says
1 studyEast Asian people taking rosuvastatin are more likely to get liver problems, and most of those people have a specific gene variant that makes this more likely — the study confirms this link.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.